Shares of GTx Inc. (GTXI) are down sharply during morning trading. On news that the FDA has asked for more data about its bone drug Toremifene, the stock gapped open lower on Monday and has added to its losses lately.
The stock is now down $3.94 to $5.03, dropping to a new 52-week low.
For comments and feedback: editorial@rttnews.com